A weekly pill organizer organized by days of the week, an ASRS screening questionnaire filled out in a home office, a telehealth intake form open on a tablet screen — this is what the beginning of an adult ADHD evaluation actually looks like in our practice. Adult ADHD is among the most commonly evaluated conditions in telehealth psychiatry, and also one of the most frequently misunderstood in terms of how the diagnosis process actually works. This article explains what to expect at each stage, so you can prepare for your evaluation and understand how clinical decisions get made.

Adult ADHD often goes undiagnosed for years. Research from the National Comorbidity Survey Replication suggests that fewer than 20 percent of adults who meet diagnostic criteria for ADHD have received formal diagnosis and treatment. The most common reason: they reached adulthood before widespread awareness that ADHD presents differently in adults than in children, and before telehealth made evaluation accessible enough to pursue.

What Adult ADHD Diagnosis Actually Involves

A clinical ADHD diagnosis in adults requires a comprehensive psychiatric evaluation against DSM-5 criteria: five or more symptoms of inattention and/or hyperactivity-impulsivity (the threshold drops from six after age 17), symptoms present since before age 12, causing functional impairment in two or more life settings, and not better accounted for by another condition. This is a clinical judgment made through interview and structured assessment — there is no blood test, no brain scan, no single instrument that renders a ADHD diagnosis by itself.

Many adults seek evaluation after years of managing poorly with strategies that used to work: caffeine-driven work sprints, hyperfocusing on high-interest tasks while neglecting others, compensating through structure that took enormous mental energy to maintain. The evaluation explores this history systematically.

The Role of Validated Screening Tools

Before your first appointment, Legion Health's intake includes the Adult ADHD Self-Report Scale (ASRS-v1.1), a 6-item screener developed with the World Health Organization, and optionally the Conners' Adult ADHD Rating Scales. These are structured self-report instruments that help your provider identify symptom clusters and structure the clinical interview — they are not tests that produce a diagnosis. Your provider interprets them alongside your personal history, not instead of it.

It is also common for providers to ask about collateral history: a partner's observations, performance reviews from work, old report cards if available. This kind of longitudinal evidence strengthens the clinical picture, particularly the childhood onset criterion that DSM-5 requires.

What Your Provider Will Explore During the Evaluation

During your 45-minute initial appointment, your psychiatrist or PMHNP will systematically ask about your symptoms across multiple functional domains: academic or work performance, time management, task completion, relationship conflicts triggered by inattention or impulsivity, and your experience since childhood. They will also conduct a differential diagnosis review, because anxiety disorders, mood disorders, sleep disorders (especially sleep apnea), and trauma can all produce inattention symptoms that mimic ADHD. Getting this differential right matters clinically: treating anxiety with stimulants when anxiety is the primary driver is not appropriate care.

“The evaluation is not a checklist exercise. It is a clinical conversation that takes your full history seriously — including the years you spent compensating before you knew what you were compensating for.”

Non-Stimulant Options and Clinical Considerations

If your provider determines that medication is clinically appropriate, stimulant medications (in the amphetamine and methylphenidate classes) remain first-line for most adults with ADHD. Non-stimulant options including atomoxetine, viloxazine, and certain antidepressants with evidence in ADHD are also considered, particularly for patients with certain comorbidities, substance use history, or cardiovascular considerations that make stimulants less appropriate. Your provider will discuss options based on your full clinical picture, not a default protocol.

Stimulant Prescribing and Telehealth Regulations

Schedule II stimulants require specific regulatory compliance. Under current DEA telemedicine prescribing rules, a synchronous telehealth visit (live video with audio) satisfies the requirement for the initial prescription — your Legion Health appointment qualifies. The prescription is sent electronically to your pharmacy via Surescripts. Monthly refills for controlled substances require ongoing telehealth follow-ups within the care relationship; your provider cannot send refills without a clinical check-in, and that requirement protects both you and your provider.

Your Care Plan After Diagnosis

Whether or not medication is prescribed, your care plan includes a structured follow-up schedule. The standard rhythm in our practice is a 30-day follow-up after starting a new medication to assess early tolerability, a 60-day visit to evaluate therapeutic response and make dose adjustments if needed, and quarterly visits thereafter for stable patients. Between appointments, the patient portal lets you submit symptom check-ins and flag concerns to your care team without waiting for your next scheduled visit.

If a first medication does not provide adequate response or produces intolerable side effects, that is clinically normal and not a sign of diagnostic error. Research suggests a meaningful proportion of people with ADHD require medication adjustments before finding the right fit. Your provider tracks this longitudinally and adjusts the plan accordingly.

Source Notes

  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 2013.
  • Kessler RC, et al. “The Prevalence and Correlates of Adult ADHD in the United States.” American Journal of Psychiatry. 2006.
  • Faraone SV, et al. “The World Federation of ADHD International Consensus Statement.” Neuroscience & Biobehavioral Reviews. 2021.
  • DEA Diversion Control Division. Telemedicine Prescribing of Controlled Substances Guidance. 2024.
  • SAMHSA. Treatment for ADHD in Adults: A Review of the Evidence. 2022.

This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider for diagnosis and treatment of any medical condition. Legion Health is not an emergency service. If you are in crisis, call or text 988 or go to your nearest emergency room.